BI Asset Management Fondsmaeglerselskab A S Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)

BI Asset Management Fondsmaeglerselskab A S boosted its position in United Therapeutics Co. (NASDAQ:UTHR) by 21.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 85,242 shares of the biotechnology company’s stock after buying an additional 14,964 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in United Therapeutics were worth $30,077,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealthfront Advisers LLC grew its holdings in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank purchased a new position in United Therapeutics during the 4th quarter valued at about $151,764,000. FMR LLC increased its holdings in United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after acquiring an additional 393,777 shares in the last quarter. Thrivent Financial for Lutherans raised its position in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after acquiring an additional 189,967 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its position in shares of United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after purchasing an additional 161,751 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 0.2 %

NASDAQ:UTHR opened at $284.73 on Friday. The business’s 50-day moving average price is $316.61 and its 200 day moving average price is $348.66. United Therapeutics Co. has a 52-week low of $233.28 and a 52-week high of $417.82. The firm has a market cap of $12.79 billion, a P/E ratio of 12.50, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period in the previous year, the firm earned $4.36 EPS. Sell-side analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $370.71, for a total value of $3,707,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $955,319.67. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company’s stock, valued at approximately $10,437,712.18. This trade represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,500 shares of company stock valued at $30,971,540. Corporate insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on UTHR. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.